araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Oslo Antioxidant Study

Summary: The primary objective of this study is to test whether increasing the total intake of antioxidants to middle-aged smoking men increases the antioxidant defence, reduces oxidative damage, and improves biomarkers for oxidative stress.
  The secondary objectives is to test whether this strategy improves other cardiovascular risk markers including platelet function, lipid levels, inflammation, and markers of endothelial damage.

Detailed description: In this study men smoking 5 or more cigarettes daily will be invited to participate. We will only include individuals with high cardiovascular risk (men rather than women, smokers rather than nonsmokers, middle-aged to elderly rather than young individuals), in order to recruit people with presumed high oxidative stress who might be most likely to show an effect and benefit from our intervention.
  at the time of inclusion, participants will be randomized to three groups; control group, kiwi group or phytochemical group. The kiwi group will consume three kiwis a day, whereas the phytochemical group will consume an array of antioxidant-rich food stuffs. The intervention period is eight weeks.
  Blood samples will be collected before and after the intervention period.

Eligibility: Inclusion Criteria:
  -  Men aged 45-75 years
  -  Daily smoker of a minimum of 5 cigarettes a day
  -  BMI <35 kg/m2 (because of difficulties that may be experienced by morbidly obese individuals in following the diet)
  -  Stable weight range of 4 kg or less during the previous 12 weeks
  Exclusion Criteria:
  -  Any symptomatic CVD (myocardial infarction, angina pectoris, CABG, PCI, CHF, NYHA class III-IV)
  -  Diabetes type I or type II taking drugs for diabetes
  -  Following a vegetarian diet or near-vegetarian diet currently
  -  Allergy to nuts, kiwi fruits, chocolate, strawberries or tomatoes
  -  Clinical disorders including gastrointestinal disease impairing compliance with dietary recommendations
  -  History of serious or unstable medical or psychiatric disorder
  -  Current use of or need of lipid lowering drug treatment, aspirin or non-steroidal anti-inflammatory drugs (NSAID), according to assessment of the primary clinical investigator. Any "over the counter" headache/ pain or cold remedies taken during the study must not contain aspirin or aspirin like drugs such as ibuprofen. These are classed as and will interfere with platelet function, making them unresponsive for a period of 10-14 days. Paracetamol, however, can be taken as an alternative if required
  -  History of alcohol/or drug abuse
  -  Participation in a drug trial during the previous 30 days
  -  Use of drugs (Xenical, Reductil), nutritional supplements or herbs for weight loss within the 4 weeks prior to visit 2 or participation in an active weight reduction program
  -  Use of single vitamin or other antioxidants (must be stopped 4 weeks prior to visit 2)
  -  Individuals judged by the clinical investigator to be unable to follow instructions and procedures of the study.

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Lung Cancer Location: a Repository

Summary: The purpose of this repository is to prospectively examine subjects with known or suspected lung cancer to determine the extent of mediastinal lymph node involvement with respect to primary lung cancer location. The data collected in this repository may be used to influence our current standard of care and streamline indications for EUS.


Eligibility: Inclusion Criteria:
  -  Subjects undergoing EUS evaluation of a mediastinal mass, or suspected/known lung cancer
  -  Subjects with a prior history of lung cancer
  -  Subjects referred to thoracic surgery for evaluation of a suspected/known lung cancer
  Exclusion Criteria:
  -  Altered mental status that would prohibit the giving and understanding of informed consent
  -  Dementia
  -  Psychiatric illness that would preclude adequate compliance with communication for this protocol
  -  Prisoners

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors

Summary: The purpose of the study is to evaluate the effectiveness of radiofrequency ablation by pathological correlation and to characterize the tissue response after treatment of primary and secondary pulmonary tumors.

Detailed description: Thermal ablation therapy is an increasingly performed technique in the local tumor treatment. Among these techniques, image-guided radiofrequency (RF) ablation attained widespread consideration in the therapy of liver tumors and osteoid osteoma. Promising results of hepatic RF ablation raised expectations to utilize the advantages of image-guided ablation therapy for the treatment of pulmonary malignancies. The purpose of the study is to evaluate the effectiveness of radiofrequency ablation by pathological correlation and to characterize the tissue response after treatment of primary and secondary pulmonary tumors. Computed tomography-guided RF ablation is performed in local or general anesthesia, followed by surgical resection three days later. An analysis of complete RF ablation and a characterization of tissue response is performed by hematoxylin and eosin staining, immunostaining, and electron microscopy. Adverse effects and complications are recorded.

Eligibility: Inclusion Criteria:
  -  Signed informed consent for radiofrequency ablation and surgery
  -  Maximum of 3 lung tumors
  -  Maximum tumor size 5 cm
  -  Must be able to receive standard surgery
  Exclusion Criteria:
  -  Pathological coagulation tests
  -  Pregnant or breast feeding
  -  Maximum tumor size more than 5 cm
  -  Bilateral secondary lung cancer with more than 3 tumors
  -  Inoperable patient

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Quantifying Lung Tumor Movement Under Deep Inspiration Breath Holds

Summary: Radiotherapy is a common treatment for lung cancer. One Challenge of delivering radiation treatment to lung tumors accurately is tumor movement which occurs as a patient breathes. In some situations, tumors move enough during breathing so that some or all of the tumor may be missed by a radiation treatment. One way to decrease the amount a lung tumor moves during radiotherapy treatments is for patients to held their breath briefly during a radiation treatment. By doing this, a patient's lung tumor may not move as much as it would during regular breathing. In this study, the investigators aim to study patients with lung cancers which move during breathing. Patients will be asked to hold their breath after inspiration while a CT scan of their lung tumor is obtained. The purpose of this study is to study how much less patients' lung tumors move when they hold their breath


Eligibility: Inclusion Criteria:
  -  biopsy confirmed primary lung cancer
  -  undergoing radiotherapy or chemoradiotherapy
  -  able to perform adequate deep inspiration breath hold
  -  patients of childbearing potential must practice adequate contraception
  -  signed study-specific informed consent form
  Exclusion Criteria:
  -  unable to perform adequate deep inspiration breath hold
  -  prior tumor resection
  -  prior chest or neck RT
  -  pregnant

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer

Summary: The purpose of this study is to determine whether Mycobacterium w in combination with Paclitaxel plus Cisplatin are effective in Advanced Non Small Cell Lung cancer.

Detailed description: Non-small cell lung cancer (NSCLC) accounts for 75% of all lung cancers. majority of patients of NSCLC patients are stage IIIA or IIIB patients are suitable for radiotherapy, which could not improve the survival rates of 5-10%. This study proposed Mycobacterium w (heat killed) in combination chemotherapy of Cisplatin and Paclitaxel along with radiotherapy for adjuvant therapy management of NSCLC in controlled clinical trial, which may prove the efficacy, better survival rate and quality of life.

Eligibility: Inclusion Criteria:
  -  Ability to understand and the willingness to sign a written informed consent document.
  -  Histologically or cytologically confirmed Non-Small Cell Cancer, Stage IIIB or IV.
  -  Age should be 18 years or above.
  -  ECOG should be in 0-1 range.
  -  Absolute neutrophil count ≥ 1,00,000/mm3
  -  hemoglobin ≥ 9.0g/dL
  -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)range of institution (5times ULN if liver metastasis present).
  -  bilirubin not greater than 1.5 times ULN range of institution (3 times ULN if liver involvement).
  -  Creatinine ≤ upper limit of normal (ULN) range of institution.
  -  Negative pregnancy test for women of child bearing potential prior to entry into the trial.
  Exclusion Criteria:
  -  Patient who have cytotoxic chemotherapy or radiotherapy prior to entering the study
  -  Patient with systematic brain metastasis.
  -  History of allergic reaction attributed to paclitaxel, cisplatin or mycobacterium w or any of their ingredients.
  -  Pregnant women or nursing women.
  -  Uncontrolled intercurrent illness that would limit compliance with study requirements.
  -  HIV positive patients.
  -  Previous splenectomy.

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: The Effect of Berries on Lung Cancer Tumors

Summary: The purpose of this study is to determine how berries affect cancer tumors in patients with non-small cell lung cancer.

Detailed description: In the United States, more people (161,840 per year) die of lung cancers than of prostate cancer, breast cancer and colon cancer combined. Presently, there are over 43 million current smokers and over 47 million ex-smokers living in the US. Due to the lag time between smoking and the development of cancer, there are significant numbers of ex-smokers and current smokers who may develop lung cancer compared to never smokers.
  Recent studies in animals have shown that berries, given as a dietary supplement, are highly effective against certain types of cancers. In a study involving mice with lung tumors, mice that had consumed a mixture of berries developed fewer tumors and had less tumor growth than mice that did not consume berries.
  The berries used in this study will consist of blueberries, black raspberries, or a mixture of both.

Eligibility: Inclusion Criteria (lung cancer survivors):
  -  men treated for lung cancer, women treated for lung cancer and with no child-bearing potential (hysterectomy, tubal ligation, post-menopausal women)
  Exclusion Criteria (lung cancer survivors):
  -  women who are on hormone replacement therapy
  -  women who are pregnant, or planning for pregnancy
  -  history of lung transplant
  -  prison inmate
  -  inability to take oral medication or food
  -  known or suspected allergy to berries or berry products
  -  HIV patients
  Inclusion Criteria (volunteers):
  -  adult men, adult women with no child bearing potential (hysterectomy, tubal ligation, post-menopausal women)
  Exclusion Criteria (volunteers):
  -  women who are on hormone replacement therapy
  -  women who are pregnant, or planning for pregnancy
  -  history of lung transplant
  -  prison inmate
  -  inability to take oral medication or food
  -  known or suspected allergy to berries or berry products
  -  HIV patients

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage

Summary: Patients with slight increase in blood pressure levels have an increased cardiovascular risk. In particular this has been demonstrated also in subjects with high-normal blood pressure in whom an exaggerated blood pressure increase, during exercise, and structural left ventricular abnormalities have been shown. On the other hand, the last American and European guidelines for management of hypertension recommend more aggressive treatment in young-middle aged subjects to achieve a better control of cardiovascular risk due to blood pressure increase. In agreement with these recommendations the investigators share the idea that a good blood pressure control should be achieved not only at rest, but also during psycho-physical stress conditions that frequently occur during daily life. On this basis, the investigators decided to evaluate the efficacy and tolerability of the association of valsartan and hydrochlorothiazide (160 an 25 mg daily, respectively) in patients with high-normal blood pressure and first degree arterial hypertension with evidence of organ damage.
  The aim of this study is to assess if an early and adequate therapy could bring to a better pressure control (even during physical activity) and a regression of organ damage without interfering with metabolism and erectile function


Eligibility: Inclusion Criteria:
  -  Aged 18-65
  -  Gender Males
  -  High-normal blood pressure (130-139 mmHg or 85-89 mmHg)
  -  First degree hypertension (140-159 mmHg or 90-99 mmHg)
  -  Cardiac remodeling (left ventricular concentric hypertrophy
  Exclusion Criteria:
  -  Coronary artery disease
  -  Secondary hypertension
  -  Diabetes mellitus
  -  Incapacity to perform ergometry test
  -  Anemia (Hb < 12.5g/dL)
  -  Cardiac valve disease
  -  Arrhythmia

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Radiofrequency Ablation of Pulmonary Tumors Response Evaluation

Summary: The study hypothesis is that the radiofrequency (RF) ablation is a safe and effective treatment for malignant lung tumors.

Detailed description: Image-guided RF ablation is accepted as a viable therapeutic choice for patients with early-stage hepatocellular carcinoma or limited hepatic metastatic disease from colorectal cancer, when surgery is precluded (1, 2). Recently, RF ablation has been proposed as a viable option for the treatment of pulmonary malignancies. Experimental studies in animal tumor models have confirmed the effectiveness of RF ablation in the destruction of experimentally-induced pulmonary malignancies (3). Pilot clinical investigations have suggested that the treatment can achieve high proportions of tumor response (4, 5). We designed a prospective, intention-to-treat, multicenter clinical trial aimed at assessing feasibility, safety and effectiveness of RF ablation in the treatment of lung malignancies.

Eligibility: Inclusion Criteria:
  1. adult (> 18 years) male or female patient
  2. patient has biopsy-proven NSCLC or lung metastasis
  3. patient has been rejected for surgery and has been considered unfit for radiation therapy or chemotherapy
  4. patient has as many as 3 tumors per lung, each 3.5 cm or smaller in greatest diameter, by CT scan
  5. tumors are located at least 1 cm from trachea; main bronchi; esophagus; aorta; aortic arch branches; pulmonary artery; and heart
  6. tumors are accessible by percutaneous route
  7. patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  8. patient has platelet count > 100 x 109 /L and international normalized ratio ≤ 1.5
  9. patient has signed written informed consent prior to any study specific procedures.
  Exclusion Criteria:
  1. patient has undergone previous pneumonectomy
  2. patient is considered at high-risk for RF ablation due to major co-morbid medical conditions
  3. patient has more than 3 tumors / lung
  4. patient has at least one tumor > 3.5 in greatest diameter
  5. tumor is associated with atelectasis or obstructive pneumonitis
  6. patient has renal failure requiring hemodialysis or peritoneal dialysis
  7. patient has active clinically serious infection
  8. patient has history of organ allograft
  9. patient has history of substance abuse or any medical, psychological or social conditions that may interfere with his / her participation in the study or evaluation of the study results
  10. patient is pregnant or breast-feeding
  11. patient has ECOG performance status > 2
  12. patient has platelet count ≤ 100 x 109 /L or international normalized ratio > 1.5.

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC

Summary: The purpose of this study is to evaluate the maximum tolerated dose, the activity and the safety profile of the combination of vorinostat and topotecan in patients with recurrent small cell lung cancer


Eligibility: Inclusion Criteria:
  -  Histologically or cytologically proven diagnosis of SCLC;
  -  Limited or extensive-stage disease in patients who have received a single chemotherapy regimen or combined modality (chemotherapy + chest radiotherapy) regimen and relapsed after completion of first-line chemotherapy (sensitive relapse);
  -  Age >/= 18 years;
  -  ECOG Performance Status 0-2;
  -  Life expectancy of at least 12 weeks;
  -  Measurable lesions according to RECIST criteria;
  -  Adequate cardiac, hepatic, renal, and bone marrow function;
  -  Written informed consent.
  Exclusion Criteria:
  -  Prior treatment with an HDAC inhibitor;
  -  Symptomatic and/or unstable pre-existing brain metastases;
  -  Superior Vena Cava Syndrome;
  -  Spinal cord compression;
  -  Severe or uncontrolled medical diseases (Hypertension, diabetes, congestive heart failure, myocardial infarction within 6 months of study, chronic renal disease, or active uncontrolled infections);
  -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ;
  -  Pregnant or breastfeeding women.

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Summary: This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with advanced solid tumors, including non small cell lung cancer.


Eligibility: Inclusion Criteria:
  Advanced solid tumor malignancy ECOG 0 or 1
  Exclusion Criteria:
  Prior treatment with with high-dose chemotherapy requiring stem cell rescue Prior irradiation to ≥25% of the bone marrow (e.g. whole pelvis=25%) Patients with centrally located lung lesions unless recently treated with radiotherapy

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease

Summary: RATIONALE: Diagnostic procedures, such as optical coherence tomography, may help find and diagnose lung cancer or precancerous cells.
  PURPOSE: This phase I trial is studying how well optical coherence tomography of the airway works in detecting abnormal cells in patients undergoing surgery for lung cancer or lung disease.

Detailed description: OBJECTIVES:
  -  Correlate optical coherence tomography images of the airway with airway histology.
  -  Develop an imaging technique to detect premalignant airway epithelial changes (carcinoma in situ, dysplasia) to study the transformation process as well as intervene and prevent the development of lung cancer.
  OUTLINE: Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery. All imaged areas are marked. The marked areas are then excised and fixed in formalin for histopathologic analysis.

Eligibility: DISEASE CHARACTERISTICS:
  -  Undergoing pneumonectomy or lobectomy for malignant or benign lung processes
  PATIENT CHARACTERISTICS:
  -  Not specified
  PRIOR CONCURRENT THERAPY:
  -  See Disease Characteristics

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Summary: This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.


Eligibility: Inclusion Criteria:
  -  advanced measurable Non-Small Cell Lung Cancer (NSCLC);
  -  progressed after 1-2 prior chemotherapy;
  -  Eastern Cooperative Oncology Group (ECOG) 0-2;
  -  tissue available for future KRAS/ EGFR testing
  Exclusion Criteria:
  -  prior Epidermal Growth Factor Receptor (EGFR) targeted therapy;
  -  active or untreated Central Nervous System (CNS) metastases;

Relevance to patient case: not relevant
Patient case: 57-year-old male with lung cancer; genetic feature: FGFR1

Clinical trial: Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007

Summary: The primary goal of this retrospective study is to evaluate the male breast cancer patient population at Summa Health System/Akron City Hospital over a period of 18 years and compare the findings to historical data.
  The objectives are to:
  -  identify risk factors.
  -  evaluate stage and histology at the time of presentation.
  -  document treatment modalities and outcomes.
  -  analyze outcomes for comparison to historical data.


Eligibility: Inclusion Criteria:
  -  Male breast cancer patients diagnosed and/or treated at Summa Health System/Akron City Hospital from the reference year of 1995 through 2007.

Relevance to patient case: not relevant